CDC Narrows RSV Vaccine Guidelines Due to Safety Concerns
The U.S. Centers for Disease Control and Prevention (CDC) has recently narrowed its original recommendations for the respiratory syncytial virus (RSV) vaccine, citing concerns over the risk of a side effect that can lead to paralysis or death. The recommendations originally stated adults over the age of 60 should receive the vaccine, but updates in […]
RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome
On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 who received a respiratory syncytial virus (RSV) vaccine developed Guillain-Barré syndrome (GBS).1 When a person develops GBS, including after an infection or […]
CDC Reports Errors in RSV Vaccines Given to Pregnant Woman, Monoclonal Antibody Shots to Children
A new problem involving the RSV (Respiratory Syncytial Virus) vaccines given to adults over age 60 and monoclonal antibody shots given to infants and children has been highlighted in a recent emergency newsletter called the U.S. Centers for Disease Control and Prevention (CDC) Clinician Outreach and Communication Activity, which is distributed to health care providers.1 […]
Twelve Infants Die During Clinical Trials for FDA-Endorsed RSV Drug
On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to provide protection for infants from respiratory syncytial virus (RSV) disease and other lower respiratory tract infections during their first year of life.1 […]
RSV Vaccine Approved by FDA for Adults 60 and Older
The U.S. Food and Drug Administration (FDA) has approved a license for the world’s first respiratory syncytial virus (RSV) vaccine to be given to people 60 years of age and older. Pharmaceutical and biotechnology company GSK (formerly GlaxoSmithKline) has already begun manufacturing doses of the vaccine, which will be sold as early as this fall […]
